Adolor receives U.S. Patent for beloxepin to treat pain

Adolor Corporation (NasdaqGM:ADLR) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,829,576 covering the use of ADL6906 (beloxepin), a small molecule, for the treatment of pain. The issued patent will expire on February 19, 2029.

“We are pleased to announce the issuance of this patent for ADL6906”

The compound was previously studied by a pharmaceutical company in late-stage clinical trials in over 1,000 patients for the treatment of depression, where it demonstrated a good safety profile. Adolor is repositioning ADL6906 as a potential treatment for pain conditions and currently is conducting Phase 1 clinical evaluation of the compound.

"We are pleased to announce the issuance of this patent for ADL6906," said Michael R. Dougherty, President and Chief Executive Officer. "ADL6906 represents an important addition to our clinical development portfolio, and we look forward to reporting on our progress in further studies."

The ongoing Phase 1 multiple ascending dose study is evaluating the safety, tolerability and pharmacokinetics (PK) of ADL6906 administered orally twice daily over 10 days in healthy volunteers.